Company intelligence / Profile preview
Endo Axiom
Haymarket, New South Wales, Australia
- Ownership
- Private
- Development stage
- Other
01
Overview
Endo Axiom has two lead programs: an oral peptide delivery platform (EA-1) for smart insulin and metabolic therapies, and an inverse vaccine (EA-2) for immune tolerance. Both have demonstrated strong efficacy in rodent and non-human primate models, with GMP manufacturing underway and Phase 1 trials planned for 2025.
- Therapeutic areas
- ImmunologyEndocrinology
- Modalities
- PeptidesNanoparticleBiologic
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
University of SydneySydney Local Health DistrictAb Initio PharmaProto Axiom
Beyond the preview
Go deeper on Endo Axiom.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endo Axiom.